Representing pharmaceutical originators
has always been one of our main areas of expertise.


The development of new drugs, applications and dosages, as well as the discovery of new indications for existing drugs, has become more and more cost-intensive over recent decades. Increasing regulatory requirements only add to these costs. 

rospatt advises and represents originators to protect their precious intellectual property in the pharmaceutical sector. This IP forms the basis for the necessary investments in innovation.

rospatt helps you to develop strategies against generic market entry and obtains preliminary injunctions against premature listing of drugs. We also assist in defending your IP rights against nullity attacks or nullifying the IP rights of the opponents, and take action against grey market imports.

Related Cases

  • AbbVie v Gilead (patent entitlement dispute)
  • Almirall v EMRAmed (Bretaris Genuair parallel import)
  • Amgen v generics (Cinacalcet)
  • Bayer v Ceva (animal nutrition)
  • Biogen v generics (Techfidera, Fampyra)
  • Janssen v Ratiopharm (Itraconazol)
  • Mundipharma v generics (Targin)
  • NovartisGSK (vaccine adjuvant)
  • Sanofi v. generics (Irbesartan)
  • Shire v CSL (HAE treatment)
  • UCBNectar Therapeutics (polymeric reagens preparation)